Fundraising Fox
Spruce Biosciences
NASDAQ: SPRBSouth San Francisco, US · Founded 2016 · Delaware corporation · 37 employees on LinkedIn · 10 known investors
Find your way into Spruce Biosciences
Each arrow is one introduction. Sign up to fill in the first one.
Ask Shawna Frazier to introduce you to RICHARD KING
You →Shawna · together at Spruce Biosciences →RICHARD
Ask Jamie Chen to introduce you to Samir Gharib
You →Jamie · together at CRC Results →Samir
Sign up to find every way you can get introduced to Spruce Biosciences
- Your email: who you already know at Spruce Biosciences, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Spruce Biosciences team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B). The company works with patients and families affected by rare neurological conditions.
Founders & leadership
Board
Investors · 10
How we know: Aisling Capital's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: HealthCap's portfolio page · the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: RiverVest Venture Partners's portfolio page · the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Also in the syndicate · 2
Reported raises · per SEC filings
Form D private placements$191.6M disclosed across 3 of 5 rounds · 1900–2026
▶$50MraisedOct 2025 · 21 investors · BiotechnologyRule 506(b)
- Kirk WaysDirector
- Javier SzwarcbergExecutive Officer, Director
- Simpson CamillaDirector
- Percival Barretto-KoDirector
- Tiba AynechiDirector
- Samir GharibExecutive Officer
- Bali MuralidharDirector
- Michael GreyExecutive Officer, Director
- Daniel SpiegelmanDirector
- Offering amount
- $50M
- Amount sold
- $50M
- Sales commissions
- $3M
- Placement agents
- Citizens JMP Securities, LLC, H.C. Wainwright & Co., LLC, Leerink Partners LLC
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$53.6MraisedFeb 2023 · 20 investors · BiotechnologyRule 506(b)
- Daniel SpiegelmanDirector
- Javier SzwarcbergExecutive Officer, Director
- Dina ChayaDirector
- Tiba AynechiDirector
- Samir GharibExecutive Officer
- Kirk WaysDirector
- Simpson CamillaDirector
- Bali MuralidharDirector
- Ralph William Charlton IIIExecutive Officer
- Michael GreyExecutive Officer, Director
- Offering amount
- $53.6M
- Amount sold
- $53.6M
- Sales commissions
- $2.4M
- Placement agents
- SVB Securities LLC
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$88MraisedAug 2020 · 11 investors · BiotechnologyRule 506(c)
- SAMIR GHARIBExecutive Officer
- RICHARD KINGExecutive Officer, Director
- TIBA AYNECHIDirector
- CAMILLA SIMPSONDirector
- NIALL O'DONNELLDirector
- JONAS HANSSONDirector
- BALI MURALIDHARDirector
- MICHAEL GREYDirector
- DINA CHAYADirector
- Offering amount
- $88M
- Amount sold
- $88M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Spruce Biosciences do?
- Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B). The company works with patients and families affected by rare neurological conditions.
- Who are Spruce Biosciences's investors?
- Spruce Biosciences's investors include Aisling Capital, HealthCap, RiverVest Venture Partners, Abingworth, Norwest Venture Partners, Novo Holdings, Omega Funds, OrbiMed.
- How much funding has Spruce Biosciences raised?
- Spruce Biosciences has disclosed $191.6M raised across 3 of its 5 known rounds.
- Where is Spruce Biosciences headquartered?
- Spruce Biosciences is headquartered in South San Francisco, US.